nounIntermediate
Definition
GLP-1 receptor agonist peptide drug (brands: Victoza for diabetes, Saxenda for obesity).

Detailed Explanation

GLP-1 receptor agonist peptide drug (brands: Victoza for diabetes, Saxenda for obesity). Liraglutide is a GLP-1 analog with one amino acid substitution (Lys34→Arg) and acylation with a C16 palmitic acid linked via a glutamic acid spacer to Lys26. This modification enables albumin binding, extending the half-life from ~2 minutes to ~13 hours for once-daily injection. Approved in 2010 for type 2 diabetes and 2014 for obesity. Liraglutide paved the way for the more potent, longer-acting semaglutide.

Key Facts

  • GLP-1 receptor agonist peptide drug (brands: Victoza for diabetes, Saxenda for obesity).
  • Liraglutide is a GLP-1 analog with one amino acid substitution (Lys34→Arg) and acylation with a C16 palmitic acid linked via a glutamic acid spacer to Lys26.
  • This modification enables albumin binding, extending the half-life from ~2 minutes to ~13 hours for once-daily injection.
  • Approved in 2010 for type 2 diabetes and 2014 for obesity.
  • Liraglutide paved the way for the more potent, longer-acting semaglutide.
Related Terms Semaglutide GLP-1 Acylation Exenatide

Part of the PeptideBond.com education network